SCHEMBL2642635

SCHEMBL2642635

Cc1nc(NC(=O)c2cc(Oc3ccccc3S(C)(=O)=O)ccc2N)cs1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 14/20 0.74
▸ PYGL P06737 1/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ GRM5 P41594 1/20 0.39
▸ HDAC3 O15379 2/20 0.38
▸ BRAF P15056 2/20 0.38
▸ HDAC4 P56524 2/20 0.38
▸ HDAC1 Q13547 2/20 0.38
▸ HDAC7 Q8WUI4 2/20 0.38
▸ HDAC2 Q92769 2/20 0.38
▸ HDAC10 Q969S8 2/20 0.38
▸ HDAC11 Q96DB2 2/20 0.38
▸ HDAC8 Q9BY41 2/20 0.38
▸ HDAC6 Q9UBN7 2/20 0.38
▸ HDAC9 Q9UKV0 2/20 0.38
▸ HDAC5 Q9UQL6 2/20 0.38
▸ GAA P10253 1/20 0.37
▸ TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14380059 0.85 GCK (1.00) GCK
SCHEMBL2642743 0.82 GCK (0.54) GCKPYGLGRM5HDAC3BRAF
SCHEMBL2643122 0.75 GCK (0.82) GCK
SCHEMBL2642545 0.72 GCK (0.76) GCK
SCHEMBL2642949 0.71 GCK (0.81) GCKGAA
SCHEMBL2643117 0.71 GCK (1.00) GCK
SCHEMBL2642904 0.70 GCK (0.80) GCKPYGLGAA
SCHEMBL2643973 0.70 GCK (0.80) GCKGAA
SCHEMBL2642293 0.69 GCK (0.77) GCK
SCHEMBL2643299 0.69 GCK (0.77) GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1496052-B1 NOVEL AMINOBENZAMIDE DERIVATIVE BANYU PHARMA CO LTD (JP) 2009-08-05 — — EP disclosed
EP-1496052-B1 NOVEL AMINOBENZAMIDE DERIVATIVE BANYU PHARMA CO LTD (JP) 2009-08-05 — — EP disclosed
US-7253188-B2 Aminobenzamide derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-07 — — US disclosed
US-7253188-B2 Aminobenzamide derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-07 — — US disclosed
US-7253188-B2 Aminobenzamide derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-07 — — US disclosed
US-20050282815-A1 Novel aminobenzamide derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-12-22 — — US disclosed
EP-1496052-A1 NOVEL AMINOBENZAMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-01-12 — — EP disclosed
EP-1496052-A1 NOVEL AMINOBENZAMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-01-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282815-A1 Novel aminobenzamide derivative GCKR, GCK, HK2 GCK 2/4885PYGL 1449/4885MAPK1 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback